Risks from drug price revisions and healthcare insurance system reforms
First written in FY2016. 15 of 33 entries say "Restated". Latest entry: 2026-10-14.
Daito Pharmaceutical moved to the "Worse" side of this theme in 2016, 4 years before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- 2026-10-14RestatedEarnings
「また、一部のOTC類似薬については2027年３月より患者負担が導入される予定であり、医療保険制度の持続可能性確保に向けた政策対応が進められております。」
OTC類似薬の患者負担導入など、医療保険制度見直しによる影響を継続して記載している。 - FY2026WorsenedAnnual report
「Meanwhile, as part of reforms to the social security system, institutional reviews are under way. From June 2026, the selected medical treatment system for long-listed products will be expanded, and from October of the same year, authorized generics (AGs) newly listed will be subject to the same drug prices as their branded originators. In addition, new patient copayments for certain OTC-like drugs are scheduled to be introduced from March 2027.」
In addition to annual drug price revisions, the text newly specifies system changes including the expansion of the selection-based medical care system, application of the same drug prices as branded products to AGs, and the introduction of patient charges for OTC-like drugs from March 2027. - FY2026-H1WorsenedAnnual report
「As part of social security system reforms, the selection-based medical care system for long-listed products is being expanded, and new patient charges for certain OTC-like drugs will be introduced from March 2027.」
In addition to drug cost containment factors such as conventional drug price revisions, the text identifies the introduction of patient charges for OTC-like drugs from March 2027 as a new system change. - FY2025WorsenedAnnual report
「The environment surrounding the pharmaceutical and generic-drug industries is expected to remain challenging, due to annual drug price revisions and measures to restrain drug costs, including reviews of insurance coverage for OTC-like drugs, as well as higher raw material costs mainly caused by the weaker yen, higher energy prices and increased personnel expenses resulting from intensifying competition to secure human resources.」
In addition to annual drug price revisions, the text specifically identifies the review of insurance coverage for OTC-like drugs as a new factor containing drug costs, and also notes increases in raw material, energy, and labor costs. - FY2025-H1MaterialisedAnnual report
「A selection-based medical care system for long-listed products (branded drugs for which generic drugs are available) was introduced on 1 October 2024. Because patients will bear one-quarter of the price difference from generic drugs, the use of generic drugs is expected to be promoted.」
The text notes the introduction on 1 October 2024 of selection-based medical care for long-listed products as a system change related to promoting the use of generic drugs. - FY2024-Q3RestatedAnnual report
「In addition to biennial drug price revisions from fiscal 2021, annual revisions have been implemented, including revisions in interim years. The business environment for the pharmaceutical industry has become increasingly challenging, and we are required to make further efforts to improve management efficiency.」
The text continues to describe the implementation of annual drug price revisions, including revisions in interim years in addition to regular revisions, and the challenging business environment. - FY2024-Q1RestatedAnnual report
「Meanwhile, in addition to biennial drug price revisions from fiscal 2021, annual revisions have been implemented, including revisions in interim years. The business environment for the pharmaceutical industry has become increasingly challenging, and we are required to make further efforts to improve management efficiency.」
The text continues to explain that annual drug price revisions, comprising regular revisions and interim-year revisions from fiscal 2021 onward, have been implemented and that the business environment has become challenging. - FY2023-Q3RestatedAnnual report
「Meanwhile, in addition to biennial drug price revisions from fiscal 2021, annual revisions have been implemented, including revisions in interim years. The business environment for the pharmaceutical industry has become increasingly challenging, and we are required to make further efforts to improve management efficiency.」
The text continues to explain that annual drug price revisions, comprising regular revisions and interim-year revisions from fiscal 2021 onward, have been implemented and that the business environment has become challenging. - FY2023-Q1RestatedAnnual report
「Meanwhile, in addition to biennial drug price revisions from fiscal 2021, annual revisions have been implemented, including revisions in interim years. The business environment for the pharmaceutical industry has become increasingly challenging, and we are required to make further efforts to improve management efficiency.」
The text continues to explain that annual drug price revisions, comprising regular revisions and interim-year revisions from fiscal 2021 onward, have been implemented and that the business environment has become challenging. - FY2022-Q3RestatedAnnual report
「While adoption of generic drugs has expanded, drug prices were revised in April 2022 and annual revisions thereafter were decided. The operating environment for the pharmaceutical industry is therefore expected to become challenging, requiring the company to make further efforts to improve management efficiency.」
The text continues to describe the impact of the April 2022 drug price revision and the resulting reforms to drug prices and the healthcare insurance system from the decision to implement annual revisions going forward. - FY2022-Q2RestatedAnnual report
「While adoption of generic drugs has expanded, drug prices were revised in April 2021 and annual revisions thereafter were decided. The operating environment for the pharmaceutical industry is therefore expected to become challenging, requiring the company to make further efforts to improve management efficiency.」
The text continues to describe the impact of the April 2021 drug price revision and the resulting reforms to drug prices and the healthcare insurance system from the decision to implement annual revisions going forward. - FY2022-Q1RestatedAnnual report
「While adoption of generic drugs has expanded, drug prices were revised in April 2021 and annual revisions thereafter were decided. The operating environment for the pharmaceutical industry is therefore expected to become challenging, requiring the company to make further efforts to improve management efficiency.」
The text continues to describe the impact of the April 2021 drug price revision and the resulting reforms to drug prices and the healthcare insurance system from the decision to implement annual revisions going forward. - FY2021-Q3MaterialisedAnnual report
「However, a drug price revision associated with the consumption tax rate increase was implemented in October 2019, and the regular drug price revision once every 2 years was implemented in April 2020. In addition, a drug price revision was implemented in April 2021, and future annual revisions had been decided. The business environment for the pharmaceutical industry was expected to become challenging」
The fiscal 2021 drug price revision, previously described as forthcoming, is now described as having been implemented, while future annual revisions are also stated to have been decided. The drug price revision risk has become even more concrete. - FY2021-Q2WorsenedAnnual report
「However, a drug price revision associated with the consumption tax rate increase was implemented in October 2019, and the regular drug price revision once every 2 years was implemented in April 2020. In addition, the fiscal 2021 drug price revision and annual revisions thereafter had been decided, and the business environment for the pharmaceutical industry was expected to become challenging. We were required to make further efforts to improve management efficiency.」
The wording changed from "is scheduled to be implemented" in the previous quarter to "has been decided to be implemented" for the fiscal 2021 drug price revision and subsequent annual revisions, increasing the certainty of the system change. - FY2021-Q1SoftenedAnnual report
「In addition, the Basic Policy on Economic and Fiscal Management and Reform 2020, approved by the Cabinet in July 2020, states that the fiscal 2021 drug price revision will be considered and decided after taking into account the impact of COVID-19, although the fiscal 2021 revision and subsequent annual revisions were scheduled to be implemented」
While the regular drug price revision in April 2020 is stated to have been implemented, the fiscal 2021 revision is to be considered and decided after taking into account the impact of COVID-19, weakening the wording from the previous "has been decided" to "is scheduled to be implemented." - FY2020-Q3MaterialisedAnnual report
「However, a drug price revision associated with the consumption tax rate increase was implemented in October 2019, and the regular drug price revision once every 2 years was implemented in April 2020. In addition, annual drug price revisions from fiscal 2021 had been decided, and the business environment for the pharmaceutical industry was expected to become challenging. We were required to make further efforts to improve management efficiency.」
The description of the regular drug price revision, which had been listed as scheduled in the previous quarter, changed to state that it had been implemented. The revision associated with the consumption tax rate increase and the decision to implement annual revisions from fiscal 2021 were also noted. - FY2020-Q2MaterialisedAnnual report
「However, a drug price revision associated with the consumption tax rate increase was implemented in October 2019, and the regular drug price revision scheduled once every 2 years was scheduled for April 2020. In addition, annual drug price revisions from fiscal 2021 had been decided, and the business environment for the pharmaceutical industry was expected to become challenging. We were required to make further efforts to improve management efficiency.」
The drug price revision in October 2019 associated with the consumption tax rate increase had been implemented, while the regular revision scheduled for April 2020 and the decision to implement annual revisions from fiscal 2021 were also noted. - FY2020-Q1RestatedAnnual report
「However, policies to contain drug costs through drug price cuts and other measures have also been announced. In December 2017, the Central Social Insurance Medical Council approved the outline of drug pricing system reforms centered on implementing annual drug price revisions from fiscal 2021, instead of once every 2 years, and significantly cutting the prices of branded drugs for which generic drugs are widely used. The business environment for the pharmaceutical industry is expected to become challenging, and we are required to make further efforts to improve management efficiency.」
The text reiterates the challenging business environment resulting from drug pricing system reforms, including annual drug price revisions from fiscal 2021 and significant price cuts for branded drugs. - FY2019WorsenedAnnual report
「Drug prices had generally been revised once every 2 years based on surveys of actual transaction prices in the market, but annual revisions have been decided from fiscal 2021.」
The description has changed from an explanation of the previous policy and reform outline to a statement that annual drug price revisions from fiscal 2021 have been decided, increasing the certainty of the drug price revision risk. - FY2019-Q3RestatedAnnual report
「Policies to contain drug costs through drug price cuts and other measures have also been announced. In December 2017, the Central Social Insurance Medical Council approved the outline of drug pricing system reforms centered on implementing annual drug price revisions from fiscal 2021, instead of once every 2 years, and significantly cutting the prices of branded drugs for which generic drugs are widely used. The business environment for the pharmaceutical industry is expected to become challenging」
The text continues to describe the impact of drug pricing system reforms, including the policy of implementing annual drug price revisions from fiscal 2021 and significant price cuts for branded drugs for which generic drugs are widely used. - FY2019-Q2WorsenedAnnual report
「Policies to contain drug costs through drug price cuts and other measures have also been announced. In December 2017, the Central Social Insurance Medical Council approved the outline of drug pricing system reforms centered on implementing annual drug price revisions from fiscal 2021, instead of once every 2 years, and significantly cutting the prices of branded drugs for which generic drugs are widely used. The business environment for the pharmaceutical industry is expected to become challenging」
The outline of drug pricing system reforms was approved, indicating annual revisions from fiscal 2021 and significant price cuts for branded drugs for which generic drugs have become widely used. The risks from reforms to drug prices and the healthcare insurance system have become more concrete and expanded. - FY2019-Q1MaterialisedAnnual report
「The medical fee revision for fiscal 2018 was implemented from April 2018, with the impact on drug prices amounting to a 7.48% decrease on a drug cost basis. The business environment for the pharmaceutical industry in Japan has become challenging.」
Regarding the April 2018 medical fee revision, the 7.48% negative impact on drug prices on a drug cost basis has become a concrete event that has already occurred. - FY2018MaterialisedAnnual report
「Drug prices had generally been revised once every 2 years based on surveys of actual transaction prices in the market, but annual revisions are also being discussed. Downward revisions averaging 5.57% across the industry were implemented in April 2016, followed by downward revisions averaging 5.86% in April 2018.」
The text newly notes that drug prices were cut by an industry average of 5.86% in April 2018, making the drug price revision risk more concrete. - FY2018-Q3RestatedAnnual report
「However, the outlook for the pharmaceutical industry remains uncertain, with the government actively debating the role of the drug pricing system in social security spending and announcing in December 2016 a policy of revising drug prices annually instead of once every 2 years. We are required to make further efforts to improve management efficiency.」
The text continues to describe uncertainty surrounding the outlook for the policy of implementing annual drug price revisions and the need to improve management efficiency. - FY2018-Q2RestatedAnnual report
「However, the outlook for the pharmaceutical industry remains uncertain, with the government actively debating the role of the drug pricing system in social security spending and announcing in December 2016 a policy of revising drug prices annually instead of once every 2 years. We are required to make further efforts to improve management efficiency.」
The text continues to describe uncertainty surrounding the outlook for the policy of implementing annual drug price revisions and the need to improve management efficiency. - FY2018-Q1WorsenedAnnual report
「However, the outlook for the pharmaceutical industry remains uncertain, with the government actively debating the role of the drug pricing system in social security spending and announcing in December 2016 a policy of revising drug prices annually instead of once every 2 years. We are required to make further efforts to improve management efficiency.」
The announcement of a policy to revise drug prices annually, rather than once every 2 years, is described as a factor contributing to uncertainty surrounding the outlook for the drug pricing system. - FY2017RestatedAnnual report
「Drug prices are generally revised every 2 years based on surveys of actual transaction prices in the market. Downward revisions averaging 2.65% across the industry were implemented in April 2014, followed by downward revisions averaging 5.57% across the industry in April 2016.」
The text continues to describe the risks of lower selling prices and an impact on performance resulting from drug price revisions and healthcare insurance system reforms. - FY2017-Q3RestatedAnnual report
「However, the outlook for the pharmaceutical industry remains uncertain, with the government actively debating the role of the drug pricing system in social security spending, and we are required to make further efforts to improve management efficiency.」
The text continues to describe uncertainty surrounding the outlook for the drug pricing system and the need to improve management efficiency. It states that there have been no material changes in business and other risks. No quantification or new occurrence specific to any individual risk is described. Under the stated framework, quantified was set to false and materialized was set to false. - FY2017-Q2RestatedAnnual report
「However, the outlook for the pharmaceutical industry remains uncertain, with the government actively debating the role of the drug pricing system in social security spending, and we are required to make further efforts to improve management efficiency.」
The text continues to describe uncertainty surrounding the outlook for reform of the drug pricing system and the need to improve management efficiency. It states that there have been no material changes in business and other risks. - FY2017-Q1MaterialisedAnnual report
「Although measures to promote the use of generic drugs were introduced through the April 2016 medical fee revision, the drug price revision was challenging for the generic drug industry, including cuts in the prices of newly listed generic drugs, and further efforts to improve management efficiency are required.」
The text states that a challenging drug price revision, including cuts in the prices of newly listed generic drugs, was implemented, making the existing drug price revision risk a concrete feature of the current business environment. - FY2016First statedAnnual report
「Drug prices are generally revised every 2 years based on surveys of actual transaction prices in the market. Downward revisions averaging 2.65% across the industry were implemented in April 2014, followed by downward revisions averaging 5.57% across the industry in April 2016.」
The text identifies lower selling prices resulting from drug price cuts and the impact on performance from healthcare insurance system reforms as risks.